Information about a real patient is presented in stages (boldface type) to expert clinicians (Drs Guagliumi, Virmani, and Finn), who respond to the information, sharing their reasoning with the reader (regular type). A discussion by the authors follows.

Patient presentation: A 43-year-old woman complained of abrupt onset of chest pain, which started while she was assisting her husband who had just been hospitalized for coronavirus disease 2019 (COVID-19) interstitial pneumonia. A 12-lead ECG performed 2 hours after symptom onset documented an ST-segment elevation in the inferior and lateral leads (Figure 1A). She was transferred to our hub center for urgent coronary angiography and primary percutaneous coronary intervention.

On admission, she was awake, complaining of persistent chest pain. She reported neither fever nor dyspnea in previous days but a transient episode of angina the day before. She was hypotensive and tachycardic (systolic blood pressure, 70 mm Hg; heart rate, 130 bpm). Coffee ground emesis was present. While she was breathing room air, her $\text{S}_2\text{O}_2$ was 100%, $\text{Pao}_2/\text{Fio}_2$ ratio was normal, and lactate was moderately increased to 4.39 mmol/L. Focused echocardiography examination revealed severe left ventricular dysfunction (ejection fraction, 25%) with global hypokinesia and inferior and lateral akinesia (Figure 1C and Movie I in the Data Supplement). A moderate pericardial effusion (13 mm) without signs of cardiac tamponade was observed. Blood test documented normal white and red cell counts, mild acute kidney and liver injury, and slightly increased high-sensitivity C-reactive protein (1.4 mg/dL). The international normalized ratio and partial thromboplastin time were in normal range. High-sensitivity troponin I was 11 795 ng/L (Figure 2).

**Dr Guagliumi:** Clinical suspicion for COVID-19 was very high given the clinical history of exposure. Very little is known about the nature of how COVID-19 infection causes injury to the heart, but the differential diagnosis at this point with ST-segment elevations and chest pain included epicardial coronary thrombosis in the inferior (likely right coronary artery) territory, myocarditis-induced electrocardiographic changes, coronary spasm, and acute pericarditis. Given the clinical history of chest pain in a relatively young woman with no coronary risk factors and marked increase of troponin, suspicion was high for myocarditis, but an acute coronary syndrome was important to rule out.

**Patient presentation (continued):** Emergency coronary angiography showed normal epicardial coronary vessels with TIMI (Thrombolysis in Myocardial Infarction) grade 2 flow in the left anterior descending artery and intense, persistent myocardial blush in the distal right coronary artery.
Because of progressive cardiogenic shock (invasive blood pressure, 60/40 mm Hg), vasopressors and intra-aortic balloon pump were initiated for hemodynamic support (Figure 1E). The patient was transferred to the intensive care unit. Chest radiography showed pulmonary congestion without signs of interstitial pneumonia (Figure 1F).

A nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2 infection by reverse-transcriptase polymerase chain reaction assays, and antiretroviral therapy (darunavir/cobicistat) was started in the intensive care unit. Blood tests for concomitant bacterial or viral infections were negative. Despite hemodynamic support, she remained hypotensive (72/34 mm Hg) with a cardiac index of 1.1 L·min⁻¹·m⁻² and oliguria (20 mL/h). Blood lactate increased, requiring escalating doses of inotropes, intubation, and mechanical ventilation. A repeat ECG showed diffuse ST-segment elevation, whereas an echocardiogram confirmed severe left ventricular dysfunction with progressive impairment of the right ventricle. Pericardial effusion was stable.

Dr Guagliumi: On the basis of the clinical presentation, the absence of epicardial coronary artery disease, and the ominous hemodynamic course in the first hours, COVID-19–related myocarditis was assumed. Because of the unstable nature of her clinical condition, it was hoped that immunosuppressive therapy might help. She was started on a high dose of methylprednisolone (1 g/d, ie, 17.2 mg/kg) and immunoglobulin infusion (60 g/d, ie, 1 g/kg). Heparin intravenous infusion was continued during intensive care unit stay as per standard practice.

Patient presentation (continued): Nevertheless, her clinical and hemodynamic conditions continued to deteriorate. Irreversible multiorgan failure developed (Figure 2). Blood cell count demonstrated platelet depletion, whereas hemoglobin was stable at 13.3 mg/dL. The partial thromboplastin time ratio rose to 6.69, and the international normalized ratio was 3.5, hinting
at an underlying acute coagulopathy. There was a marked increase in plasminogen activator inhibitor, prothrombin activation fragments (F1 and F2), and plasma level of von Willebrand factor (Figure 2). Despite intensive management and hemodynamic support, the patient died on the 46th hour after admission.

Dr Guagliumi: Although we were in the midst of the worst of the COVID-19 pandemic in Italy, because of the remaining diagnostic uncertainties and the tragic outcome, we asked Drs Gianatti and Sonzogni to perform a complete autopsy. Given the expertise of CVPath for cardiac pathology, the heart and some selected organs (ie, lung, spleen, kidney) were sent for analysis.

Pathological examination: The heart weight was 285 g. There was right coronary dominance with mild atherosclerosis (<40% cross-sectional area narrowing of all major coronary arteries, ie, <25% diameter reduction), consistent with the patient’s angiogram. The ventricles were sliced parallel to the atrioventricular sulcus at 1- to 1.5-cm intervals, and a focal regional infarction involving the lateral and inferior wall of the left ventricle was visible as rounded focal areas measuring 2 to 3 mm in diameter that extended from the endocardium to the epicardium (Figure 3A). Similar areas were also observed in the inferior wall of the right ventricle. There was mottling of the subendocardial region of the septum and anterior wall. All 4 valves were normal. Histo-

logically examination confirmed the presence of circumferential, patchy areas of myocardial necrosis with contraction band necrosis and focal, interstitial acute inflammatory infiltrate with foci of mild hemorrhage (Figure 3B through 3D). In addition, small vessels showing platelet/fibrin thrombi were prominent in the areas of myocardial necrosis with inflammation, which stained positive for fibrin and CD61, and with a positive immunofluorescence for VE-cadherin (endothelial marker) and CD61/CD42b (platelet marker; Figure 3E through 3I). All sections showed changes in terminal ischemia with hypereosinophilic fibers and contraction band formation in the right and left ventricular walls, consistent with shock. Lung sections showed focal areas of pulmonary edema and few microthrombi in small alveolar capillaries (Figure 3J). Rare microthrombi were also observed in the kidney with greater frequency and in the spleen (Figure 3K and 3L).

Dr Virmani: The pathological examination suggested microvascular thrombi in the inferior wall of the left and right ventricles as the initial cause of the ST-segment–elevation myocardial infarction. Acute inflammatory infiltrates in these territories, together with contraction band necrosis, suggested an infarct of ≈1 to 2 days, consistent with the onset of her chest pain

Clinical course and Laboratory Tests

| ECG | Time course | Event / Treatment | Vital sign | Lab data |
|-----|-------------|-------------------|------------|---------|
| 12-lead ECG | Onset 2h | Abrupt chest pain | BP (mmHg) HR (bpm) | PCO2 (mmHg) PCO2 (mmHg) Lactates (mmol/L) TnI (ng/mL) AST/ALT (U/L) sCre (mg/dL) PLT (10⁹/mm³) PT-INR |
| Abrupt chest pain | 100/60 | 138 | - | - | - | 76/65 | 1.45 | 340 | 0.98 | 0.09 |
| Hospitalization | 60/40 | 130 | 101 | 20 | 4.39 | 182/97 | - | - | - | - |
| Transfer for Coronary angiography | 90/60 | 140 | - | - | 6.5 | 11795 | 182/97 | 1.24 | 327 | 3.24 | 1.27 |
| Vasopressors + IABP | 72/34 | 145 | 61 | 80 | 14.38 | 21490 | 979/536 | 2.02 | 242 | 1.66 | 1.75 |
| Transfer to the ICU | 50/37 | 101 | 348 | 31 | 23.54 | 45844 | 6000/2507 | 3.11 | 77 | 6.69 | 3.5 |

Figure 2. Hospital course and laboratory tests.
A timeline of the patient’s clinical course including vital signs and relevant laboratory tests is shown. aPTT indicates activated partial thromboplastin time; AST/ALT, aspartate transaminase/alanine aminotransferase; BP, blood pressure; HR, heart rate; IABP, intra-aortic balloon pump; ICU, intensive care unit; IVIG, intravenous immunoglobulin; PLT, platelet; PT-INR, prothrombin time–international normalized ratio; sCre, serum creatinine; and TnI, troponin I.
(ie, 46 hours before presentation). The pathological cause of death was cardiogenic shock resulting from myocardial necrosis that was extensive through the left ventricle and part of the right ventricle and likely caused by poor perfusion of the heart.

Molecular analysis: Molecular analysis of RNA extracted from the lungs and various areas of the heart revealed the presence of virus in the lungs, but it was undetectable in all areas of the heart. Through polymerase chain reaction, interleukin (IL)-6, a major cytokine associated with thrombosis and disease progression in patients with COVID-19, was found in the inferior wall, septum, and right ventricle (Figure 3L).

Dr Finn: Polymerase chain reaction examination showed that severe acute respiratory syndrome coronavirus 2 was present in the lungs of this subject, although there was no evidence of diffuse alveolar damage, a pattern typical of COVID-19 infection. Even with the presence of microvascular thrombi, there was no evidence of viral infection in any part of the heart.

DISCUSSION

COVID-19 infection continues to be a major cause of mortality throughout the world. Cardiac injury as
indicated by elevated levels of cardiac troponins increases risk of death, but the pathogenesis of cardiac injury remains uncertain. A better mechanistic understanding is needed to guide potential candidate therapies to improve outcomes.

In a case series from New York involving 18 patients with confirmed diagnosis of COVID-19 and ST-segment elevation, 44% received a diagnosis of acute coronary thrombosis causing myocardial infarction, and 56% had evidence of noncoronary myocardial injury (defined as either nonobstructive disease on coronary angiography or normal wall motion). Of those with noncoronary myocardial injury, 90% died in this series, suggesting a desperate need to better understand its pathogenesis and how best to treat it.

Although many studies have focused on pulmonary findings of COVID-19, few pathology studies have been conducted specifically examining the effects of COVID-19 on the heart, and most of these did not involve subjects with ST-segment–elevation myocardial infarction or even cardiac injury. The largest published pathology series that included analysis of the heart are listed in the Table.\textsuperscript{1–5} Of the collective 67 hearts examined, in 5 cases, investigators found some evidence of lymphocytic myocarditis of unclear extent and nature.

Given the low overall expression of angiotensin-converting enzyme 2 receptor in myocardial cells, tropism of severe acute respiratory syndrome coronavirus 2 for the heart may not be likely. Indeed, quantification of viral load in 22 patients dying of COVID-19 in Germany showed extremely low to no viral load in the heart in all cases. In the case report presented here, similar results were found, with no detectable virus in several sections of myocardial tissue despite multiple microemboli in the heart with virus readily detectable in the lung.

Although clinical COVID-19 cases with myocardial injury and normal coronary arteries have been reported and thought to be caused by myocarditis, here we show for the first time that ST-segment–elevation myocardial infarction may be caused by extensive microvascular thrombosis in the absence of epicardial coronary obstruction. A larger series of autopsy cases from patients with COVID-19 with evidence of myocardial injury is needed to determine how frequently cardiac microthrombi contribute to myocardial damage in the absence of coronary epicardial thrombosis. Until then, physicians should keep this possibility in mind when treating these patients.

Although direct infection of the lungs with resulting multifocal pneumonia is thought to be the major cause of death in patients with COVID-19, inflammatory cytokine syndrome may also be an important cause of morbidity and mortality. Levels of IL-8, IL-6, tumor necrosis factor-\(\alpha\), monocyte chemoattractant protein-1, and regulated upon activation, normal T cell expressed and presumably secreted (RANTES) are significantly elevated in severe COVID-19 cases and IL-6 and IL-8 have been associated with disease progression. It is thought that severely ill patients with COVID-19 are at an increased risk for thromboembolic events, including pulmonary microthrombi and venous thrombosis perhaps resulting from cytokine storm. Here, we present a case with extensive cardiac microthrombi that were a direct cause of myocardial ischemia in the absence of epicardial coronary occlusion. This type of injury would not be detectable clinically because no laboratory test can specifically detect microthrombi. In this case, infarction of the inferior and lateral walls of the left ventricle with right ventricular involvement was the likely cause of cardiogenic shock and death.

Physicians should be aware of this possible complication and of the potential of anticoagulant and

---

**Table. Published Autopsy Series of COVID-19 That Included Heart Analysis**

| Location of Case Series | No. of Hearts Examined | Description                                      | Findings                                               | Reference |
|-------------------------|------------------------|--------------------------------------------------|-------------------------------------------------------|-----------|
| New Orleans, Louisiana, USA | 9                      | Blacks from New Orleans                          | Nonspecific myocyte necrosis with rare lymphocytes, 2 with evidence of significant myocardial injury (ie, troponin I >50 ng/mL) | 1         |
| Augsburg, Germany       | 10                     | Cases from Augsburg; ages 64–90 y                 | Mild lymphocytic myocarditis in 4 cases; cardiac injury not reported | 2         |
| Mount Sinai, New York, USA | 25                    | Cases from Mount Sinai Health System; ages 34–94 y | Two cases of patchy mild interstitial chronic inflammation; 3 cases with small vessel thrombi; cardiac injury not reported | 3         |
| Styria, Austria         | 11                     | Cases from Hospital Graz II; ages 66–91 y         | One case with intramyocardial mural thrombi; 1 case with focus of fragmented cardiomyocytes with lymphocytic/granulocytic reaction; 2 cases with elevated troponin levels | 4         |
| Hamburg, Germany        | 12                     | Mandated autopsies from the State of Hamburg; ages 52–87 y | One case of lymphocytic myocarditis in right ventricle; cardiac injury not reported | 5         |

COVID-19 indicates coronavirus disease 2019.
anticytokine therapies as conceivable therapeutic options, which need to be further explored in clinical trials. In such cases when there is evidence of cardiac injury as indicated by elevated troponins and wall motion abnormalities but no evidence of epicardial coronary occlusion, the possibility of myocardial microthrombosis should be entertained and appropriate treatment initiated.

CONCLUSIONS
The case presented here challenged the traditional differential diagnosis of ST-segment-elevation myocardial infarction in the setting of COVID-19 and revealed the potential for microvascular thrombi in the absence of epicardial coronary artery disease to be a cause of acute myocardial infarction. The curiosity of the treating physicians led to further analysis of autopsy, which revealed a novel mechanism by which COVID-19 could cause cardiac injury.

ARTICLE INFORMATION
The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.120.049294.

Correspondence
Aloke V. Finn, MD, Medical Director, CVPath Institute Inc, 19 Firstfield Road, Gaithersburg, MD 20878. Email afinn@cvpath.org

Affiliations
Interventional Cardiology, Cardiovascular Department (G.G., I.P., D.P.) and Pathology Unit (A.S.), Ospedale Papa Giovanni XXIII Bergamo, Italy. CVPath Institute, Inc, Gaithersburg, MD (A.V.F.). University of Maryland, Baltimore (A.V.F.).

Acknowledgments
The authors thank the following individuals from Papa Giovanni XXIII Hospital: Andrea Gianatti from the Pathology Unit for processing the pathology samples; Matteo Brivio from the Anesthesiology and Reanimation 2 for collecting hemodynamic data in the intensive care unit; Antonio Bellasi from Clinical Trial Center, Research and Innovation for helping to devise and process the agreement with CVPath; Lara Faggi from the Cardiology Department for data collection and center coordination; and Marina Marchetti from Immunohematology and Blood Transfusion Medicine for analysis of coagulation parameters and support in data interpretation. The authors thank (from CVPath) Renu Virmani for autopsy analysis; Riki Kawakami for autopsy analysis; Atsushi Sakamoto for autopsy analysis and RNA extraction and analysis; Kenji Kawai for autopsy and RNA analysis; Bob Kutys for grossing expertise of the heart; and Maria Romero for autopsy analysis.

Sources of Funding
The study was funded by CVPath Institute, a 501(c)(3) organization.

Disclosures
Dr Guagliumi has received institutional research grants from Abbott Vascular, Boston Scientific, and Infrarex and is a consultant to Abbott Vascular and Boston Scientific. CVPath Institute has received institutional research support from grant no. R01 HL141425; Leducq Foundation Grant; 480 Biomedical; 4C Medical; 4Tech; Abbott; Accumedical; Amgen; Biosensors; Boston Scientific; Cardiac Implants; Celonova; Claret Medical; Concept Medical; Cook; CSI; DuNing, Inc; Edwards LifeSciences; Emboline; Endotronic; Envision Scientific; Lutonix/Bard; Gateway; Lifetech; Limflo; MedAlliance; Medtronic; Mercator; Meril; Microport Medical; Microvention; Mitrailign; Mitra assist; NAMS/A; Nanova; Neovasc; Nipro; Novogate; Occulotech; OrbusNeich Medical; Phenox; Profusa; Protembis; Pool; Recor; Senseonics; Shockwave; Sinomed; Spectranetics; Suri-modics; Symic; Vesper; W.L. Gore; and Xeltis. Dr Finn has received honoraria from Abbott Vascular, Biosensors, Boston Scientific, Celonova, Cook Medical, CSI, Lutonix Bard, Sinomed, and Terumo Corp; he is a consultant to Amgen, Abbott Vascular, Boston Scientific, Celonova, Cook Medical, Lutonix Bard, and Sinomed. The other authors report no conflicts.

Supplemental Materials
Data Supplement Movies I–III

REFERENCES
1. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681–686. doi:10.1016/S2213-2600(20)30243-5
2. Schaller T, Hirschbuhl K, Burkhardt K, Braun G, Trepel M, Markl B, Claus R. Postmortem examination of patients with COVID-19. JAMA. 2020;323:2518–2520. doi:10.1001/jama.2020.8907
3. Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, Hernandez T, Stock A, Zhao Z, Al Rasheed M, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response: the Mount Sinai COVID-19 autopsy experience [published online May 22, 2020]. medRxiv. doi:10.1101/2020.05.18.2009960. https://www.medrxiv.org/content/10.1101/2020.05.18.2009960v1.
4. Lax SF, Skok K, Zechner P, Kaufmann N, Koeblinger C, Vander K, Bargfrieder U, Trauner M. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series [published online May 14, 2020]. Ann Intern Med. doi:10.7326/M20-2566. https://www.acpjournals.org/doi/full/10.7326/M20-2566?url_ver=Z39.88-2003&ffr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.
5. Wichmann D, Sperhake JP, Lughezzani M, Steurer M, Edler C, Heinemann A, Heinrich F, MuskHumb M, Kniep I, Schroder AS, et al. Autopsy findings and venous thromboembolism in patients with COVID-19 [published online May 6, 2020]. Ann Intern Med. doi:10.7326/M20-2003. https://www.acpjournals.org/doi/full/10.7326/M20-2003?url_ver=Z39.88-2003&ffr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

August 25, 2020 809

Circulation. 2020;142:804–809. DOI: 10.1161/CIRCULATIONAHA.120.049294